Arixa Pharmaceuticals

Arixa Pharmaceuticals is developing oral antibiotics for resistant Gram-negative infections, an urgent need. Their lead program is an oral prodrug of Avibactam, a broad spectrum beta-lactamase inhibitor recently approved by FDA. They have addressed and solved the medicinal chemistry issues which complicate the prodrugging of this class of compounds, and expect to receive broad composition of matter patent protection.